NCT01885585已完成不适用
Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Number of Adverse Events (AEs) and serious AEs
研究概览
简要总结
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed data release
- •Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty
排除标准
- •Being treated for an indication not approved for the use of Eliquis® in Korea
- •Is contraindicated for the use of Eliquis® as described in the Korean label
研究组 & 干预措施
Patients with risk of VTE
Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
干预措施: Apixaban (Drug)
结局指标
主要结局
Number of Adverse Events (AEs) and serious AEs
时间窗: Up to 30 days after last study drug dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In KoreaDiabetes Mellitus Type 2NCT02090673AstraZeneca1,711
已完成
不适用
Eliquis Regulatory Post Marketing SurveillanceNonValvular Atrial FibrillationNCT01885598Bristol-Myers Squibb3,335
已完成
不适用
ABF Tourette's Disorder Post Marketing Surveillance StudyTourette's DisorderNCT01795105Korea Otsuka Pharmaceutical Co., Ltd.692
进行中（未招募）
不适用
Iclusig PMS in CML or Ph+ALL PatientsChronic Myeloid LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic LeukemiaNCT03709017Korea Otsuka Pharmaceutical Co., Ltd.50
已完成
不适用
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 DisorderBipolar 1 DisorderSchizophreniaNCT03386851Korea Otsuka Pharmaceutical Co., Ltd.1,030